Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102


Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.

Ming Z, Lim SY, Kefford RF, Rizos H.

Pigment Cell Melanoma Res. 2019 Sep 13. doi: 10.1111/pcmr.12824. [Epub ahead of print]


Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.


Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.

Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM.

Lancet Oncol. 2019 Jul;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6. Epub 2019 Jun 3.


Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery.

Wang G, Fu L, Walker A, Chen X, Lovejoy DB, Hao M, Lee A, Chung R, Rizos H, Irvine M, Zheng M, Liu X, Lu Y, Shi B.

Biomacromolecules. 2019 May 13;20(5):2148-2158. doi: 10.1021/acs.biomac.9b00494. Epub 2019 Apr 24.


Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.

Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch JR, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H.

Ann Oncol. 2019 May 1;30(5):815-822. doi: 10.1093/annonc/mdz075.


Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma.

Zhang X, Tang JZ, Vergara IA, Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, McIntosh L, Mitchell KA, Shaw E, Rizos H, Long GV, Hayward N, McArthur GA, Papenfuss AT, Harvey KF, Shackleton M.

Mol Cancer Res. 2019 Jul;17(7):1435-1449. doi: 10.1158/1541-7786.MCR-18-0407. Epub 2019 Mar 4.


Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.

Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, Scolyer RA, Long GV, Wilmott JS.

Cancer Cell. 2019 Feb 11;35(2):238-255.e6. doi: 10.1016/j.ccell.2019.01.003.


Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.

Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, Lim SY, Nur Gide T, Shang P, Attrill GH, Madore J, Edwards J, Carlino MS, Guminski A, Saw RPM, Thompson JF, Ferguson PM, Palendira U, Menzies AM, Long GV, Scolyer RA, Wilmott JS.

Oncoimmunology. 2018 Oct 31;8(2):e1537581. doi: 10.1080/2162402X.2018.1537581. eCollection 2019.


Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.

Kim HY, Duong JK, Gonzalez M, Long GV, Menzies AM, Rizos H, Lim SY, Lee J, Boddy AV.

Cancer Chemother Pharmacol. 2019 Apr;83(4):693-704. doi: 10.1007/s00280-019-03780-y. Epub 2019 Jan 19.


Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.

Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM.

Clin Cancer Res. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10.


Evaluation of commercial kits for purification of circulating free DNA.

Diefenbach RJ, Lee JH, Kefford RF, Rizos H.

Cancer Genet. 2018 Dec;228-229:21-27. doi: 10.1016/j.cancergen.2018.08.005. Epub 2018 Aug 29.


Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.

Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Breen EJ, Yang JYH, Ghazanfar S, Kefford RF, Scolyer RA, Long GV, Rizos H.

Clin Cancer Res. 2019 Mar 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8.


Monitoring Melanoma Using Circulating Free DNA.

Diefenbach RJ, Lee JH, Rizos H.

Am J Clin Dermatol. 2019 Feb;20(1):1-12. doi: 10.1007/s40257-018-0398-x. Review.


Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Irvine M, Stewart A, Pedersen B, Boyd S, Kefford R, Rizos H.

Oncogenesis. 2018 Sep 20;7(9):72. doi: 10.1038/s41389-018-0081-3.


Interferon Signaling Is Frequently Downregulated in Melanoma.

Alavi S, Stewart AJ, Kefford RF, Lim SY, Shklovskaya E, Rizos H.

Front Immunol. 2018 Jun 21;9:1414. doi: 10.3389/fimmu.2018.01414. eCollection 2018.


Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.

Lim SY, Rizos H.

Mamm Genome. 2018 Dec;29(11-12):866-878. doi: 10.1007/s00335-018-9757-4. Epub 2018 Jul 2. Review.


Oncogenic signaling in uveal melanoma.

Park JJ, Diefenbach RJ, Joshua AM, Kefford RF, Carlino MS, Rizos H.

Pigment Cell Melanoma Res. 2018 Nov;31(6):661-672. doi: 10.1111/pcmr.12708. Epub 2018 May 23. Review.


Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS.

JAMA Oncol. 2018 May 1;4(5):717-721. doi: 10.1001/jamaoncol.2017.5332.


Liquid biomarkers in melanoma: detection and discovery.

Lim SY, Lee JH, Diefenbach RJ, Kefford RF, Rizos H.

Mol Cancer. 2018 Jan 17;17(1):8. doi: 10.1186/s12943-018-0757-5. Review.


HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.

Gallagher SJ, Gunatilake D, Beaumont KA, Sharp DM, Tiffen JC, Heinemann A, Weninger W, Haass NK, Wilmott JS, Madore J, Ferguson PM, Rizos H, Hersey P.

Int J Cancer. 2018 May 1;142(9):1926-1937. doi: 10.1002/ijc.31199. Epub 2017 Dec 20.


Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.

Lim SY, Lee JH, Welsh SJ, Ahn SB, Breen E, Khan A, Carlino MS, Menzies AM, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 Nov 10;5:32. doi: 10.1186/s40364-017-0112-9. eCollection 2017.


PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.


EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, Fereday S, Mitchell C, Chiew YE, Hendley J, Sharma R, Harnett PR, Li J, Christie EL, Patch AM, George J, Au-Yeung G, Mir Arnau G, Holloway TP, Semple T, Pearson JV, Waddell N, Grimmond SM, Köbel M, Rizos H, Lomakin IB, Bowtell DDL, deFazio A; Australian Ovarian Cancer Study Group.

Cancer Res. 2017 Aug 15;77(16):4268-4278. doi: 10.1158/0008-5472.CAN-16-2224. Epub 2017 Jun 23.


Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.

Lim SY, Menzies AM, Rizos H.

Cancer. 2017 Jun 1;123(S11):2118-2129. doi: 10.1002/cncr.30435. Review.


Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.

Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, Long GV, Rizos H.

Biomark Res. 2017 May 11;5:17. doi: 10.1186/s40364-017-0098-3. eCollection 2017.


The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.

Wilmott JS, Rizos H, Scolyer RA, Long GV.

Clin Cancer Res. 2017 Jun 15;23(12):2921-2923. doi: 10.1158/1078-0432.CCR-17-0669. Epub 2017 May 3.


Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.

Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA.

Cancer Discov. 2017 Aug;7(8):832-851. doi: 10.1158/2159-8290.CD-16-0955. Epub 2017 Apr 28.


Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H.

Ann Oncol. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026.


The Role of Sumoylation in Senescence.

Scurr LL, Haferkamp S, Rizos H.

Adv Exp Med Biol. 2017;963:215-226. doi: 10.1007/978-3-319-50044-7_13. Review.


Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

Welsh SJ, Rizos H, Scolyer RA, Long GV.

Eur J Cancer. 2016 Jul;62:76-85. doi: 10.1016/j.ejca.2016.04.005. Epub 2016 May 24. Review.


Melanocyte reprogramming requires chromatin and transcription remodelling.

Welsh SJ, Rizos H.

Pigment Cell Melanoma Res. 2016 May;29(3):260-1. doi: 10.1111/pcmr.12457. Epub 2016 Mar 3. No abstract available.


Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.


Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M.

Oncotarget. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788.


Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

Carlino MS, Long GV, Kefford RF, Rizos H.

Crit Rev Oncol Hematol. 2015 Dec;96(3):385-98. doi: 10.1016/j.critrevonc.2015.08.021. Epub 2015 Aug 28. Review.


The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT.

Sci Signal. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.


The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function.

Tembe V, Martino-Echarri E, Marzec KA, Mok MT, Brodie KM, Mills K, Lei Y, DeFazio A, Rizos H, Kettle E, Boadle R, Henderson BR.

Cell Signal. 2015 Sep;27(9):1763-71. doi: 10.1016/j.cellsig.2015.05.011. Epub 2015 Jun 3.


Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.

Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P.

PLoS One. 2015 Apr 6;10(4):e0123410. doi: 10.1371/journal.pone.0123410. eCollection 2015.


Resistance to c-Kit inhibitors in melanoma: insights for future therapies.

Carlino MS, Todd JR, Rizos H.

Oncoscience. 2014 Jun 6;1(6):423-6. eCollection 2014.


Oncolytic virotherapy using herpes simplex virus: how far have we come?

Sokolowski NA, Rizos H, Diefenbach RJ.

Oncolytic Virother. 2015 Nov 25;4:207-19. doi: 10.2147/OV.S66086. eCollection 2015. Review.


Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, Scolyer RA, Kefford RF, Rizos H.

Nat Commun. 2014 Dec 2;5:5694. doi: 10.1038/ncomms6694.


Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Carlino MS, Fung C, Shahheydari H, Todd JR, Boyd SC, Irvine M, Nagrial AM, Scolyer RA, Kefford RF, Long GV, Rizos H.

Clin Cancer Res. 2015 Jan 1;21(1):98-105. doi: 10.1158/1078-0432.CCR-14-0759. Epub 2014 Nov 4.


Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA.

Cancer Res. 2014 Dec 1;74(23):7037-47. doi: 10.1158/0008-5472.CAN-14-1392. Epub 2014 Oct 8.


Silencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemia.

Cisterne A, Baraz R, Khan NI, Welschinger R, Basnett J, Fung C, Rizos H, Bradstock KF, Bendall LJ.

PLoS One. 2014 Jul 25;9(7):e103383. doi: 10.1371/journal.pone.0103383. eCollection 2014.


Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

Gallagher SJ, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W, Jin L, Pupo G, Cullinane C, McArthur GA, Tummino PJ, Rizos H, Hersey P.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1126-37. doi: 10.1111/pcmr.12282. Epub 2014 Jul 3.


The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

Gallagher SJ, Mijatov B, Gunatilake D, Tiffen JC, Gowrishankar K, Jin L, Pupo GM, Cullinane C, Prinjha RK, Smithers N, McArthur GA, Rizos H, Hersey P.

J Invest Dermatol. 2014 Nov;134(11):2795-2805. doi: 10.1038/jid.2014.243. Epub 2014 Jun 6.


WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.

Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, Yang PT, Chen HW, Haydu L, Toroni RA, Lucero OM, Chien AJ, Moon RT.

J Clin Invest. 2014 Jul;124(7):2877-90. doi: 10.1172/JCI70156. Epub 2014 May 27.


Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.

Chien AJ, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT, Long GV.

PLoS One. 2014 Apr 14;9(4):e94748. doi: 10.1371/journal.pone.0094748. eCollection 2014.


Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF, Rizos H.

Mol Oncol. 2014 May;8(3):544-54. doi: 10.1016/j.molonc.2014.01.003. Epub 2014 Jan 15.


Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA.

Cancer Discov. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27.


BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV.

Clin Cancer Res. 2014 Apr 1;20(7):1965-77. doi: 10.1158/1078-0432.CCR-13-3122. Epub 2014 Jan 24.

Supplemental Content

Support Center